Giuseppe Giaccone

Q: What Schools Are Affiliated With Giuseppe Giaccone

Giuseppe Giaccone is affiliated with the following schools: Harvard University, Heidelberg University, Indiana University, Kyushu University, Charles University, Utrecht University, University of Turin, Massachusetts General Hospital, Seoul National University, Indiana University Bloomington, Osaka Metropolitan University, Vrije Universiteit Amsterdam, Vilnius University, Georgetown University, Johns Hopkins University

Giuseppe Giaccone's AcademicInfluence.com Rankings

Giuseppe Giaccone

Medical

#1034

World Rank

#1328

Historical Rank

Oncology

#38

World Rank

#41

Historical Rank

medical Degrees

Giuseppe Giaccone

Philosophy

#3602

World Rank

#5791

Historical Rank

Logic

#1268

World Rank

#1973

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Giuseppe Giaccone's Degrees

Doctorate Medicine University of Turin
PhD Oncology University of Turin

Why Is Giuseppe Giaccone Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Giuseppe Giaccone's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (2003) (2937)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer (2016) (2632)
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. (2004) (1790)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. (2004) (1779)
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. (2014) (1364)
Targeting the dynamic HSP90 complex in cancer (2010) (1360)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. (2010) (1226)
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology (2013) (1093)
Cell Death Independent of Caspases: A Review (2005) (935)
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009) (870)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. (2005) (618)
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. (2003) (605)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. (2020) (587)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. (2005) (577)
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. (2007) (573)
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. (2002) (513)
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. (1998) (499)
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. (2011) (494)
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. (2013) (464)
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. (2013) (463)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer (2012) (442)
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials (2009) (386)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2015) (373)
Classification of current anticancer immunotherapies (2014) (357)
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. (2003) (355)
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. (2003) (348)
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. (2008) (317)
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors (2014) (300)
Update on Hsp90 inhibitors in clinical trial. (2009) (292)
Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer (2010) (291)
A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. (1994) (290)
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. (1998) (289)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2017) (284)
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. (2002) (277)
Apoptosis: target of cancer therapy. (2002) (277)
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer (2012) (275)
Global histone modifications predict prognosis of resected non small-cell lung cancer. (2007) (270)
Circulating Vα24+ Vβ11+ NKT Cell Numbers Are Decreased in a Wide Variety of Diseases That Are Characterized by Autoreactive Tissue Damage (2001) (264)
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. (2011) (253)
A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus (2006) (253)
Refining the treatment of NSCLC according to histological and molecular subtypes (2015) (253)
Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. (1990) (247)
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. (2015) (245)
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer (2002) (238)
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. (2015) (237)
Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. (1995) (233)
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. (2018) (229)
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. (2005) (229)
Clinical Perspectives on Platinum Resistance (2012) (227)
Alien species along the Italian coasts: an overview (2010) (224)
Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. (2009) (223)
Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. (2000) (213)
Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. (2000) (212)
FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. (1997) (211)
The Integrated Genomic Landscape of Thymic Epithelial Tumors. (2018) (210)
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. (2006) (207)
Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study (2006) (207)
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. (2013) (206)
Cathepsin B Mediates Caspase-Independent Cell Death Induced by Microtubule Stabilizing Agents in Non-Small Cell Lung Cancer Cells (2004) (204)
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. (2015) (203)
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. (2015) (198)
Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. (1998) (197)
The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (197)
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. (2015) (196)
Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. (1996) (194)
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies (2005) (191)
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). (2007) (191)
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). (2011) (190)
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. (1997) (183)
Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor (2002) (179)
Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies (2005) (178)
Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. (1996) (176)
Check-list of Mediterranean Seaweeds. I. Fucophyceae (Warming, 1884) (1992) (174)
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). (2005) (174)
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors (2014) (173)
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. (2006) (172)
Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. (2000) (172)
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors (2012) (170)
Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. (1997) (170)
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. (2009) (161)
Thymomas: A review of 169 cases, with particular reference to results of surgical treatment (1986) (161)
Selective Decrease in Circulating Vα24+Vβ11+ NKT Cells During HIV Type 1 Infection1 (2002) (160)
CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. (2002) (159)
An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer (2009) (157)
Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells (2008) (157)
Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). (2000) (153)
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors (2017) (152)
The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification (2016) (152)
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. (1999) (148)
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. (2000) (148)
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. (2007) (146)
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. (2011) (146)
Multidrug resistance gene (P-glycoprotein) expression in the human fetus. (1992) (145)
Differential expression of the c‐kit proto‐oncogene in germ cell tumours (1995) (144)
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. (2015) (144)
SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. (2016) (143)
Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. (1993) (142)
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? (2016) (141)
Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. (2001) (139)
Cortisol is transported by the multidrug resistance gene product P-glycoprotein. (1993) (139)
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. (1999) (138)
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. (1992) (138)
A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib (2014) (133)
Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival (2008) (133)
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. (2010) (133)
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. (2012) (131)
The immunoregulatory role of CD1d-restricted natural killer T cells in disease. (2004) (130)
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors (2010) (129)
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. (2006) (128)
Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. (2001) (127)
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. (2014) (127)
Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. (2010) (126)
CPT‐11 in human colon‐cancer cell lines and xenografts: Characterization of cellular sensitivity determinants (1997) (126)
Expression of drug resistance proteins in breast cancer, in relation to chemotherapy (1997) (124)
Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. (2000) (124)
IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC (2019) (121)
Population pharmacokinetic analysis of sorafenib in patients with solid tumours. (2011) (121)
Check-list of Mediterranean Seaweeds. II. Chlorophyceae Wille s.l. (1993) (121)
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. (2013) (120)
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. (2010) (120)
Thymic malignancies: from clinical management to targeted therapies. (2011) (120)
Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients (2006) (120)
Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. (1997) (120)
Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. (1988) (120)
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report (2006) (118)
Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. (2001) (118)
p53 and chemosensitivity. (1999) (118)
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). (2011) (118)
Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential Target (2008) (118)
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. (2010) (118)
A phase II study of gemcitabine in patients with malignant pleural mesothelioma (1999) (117)
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. (2004) (117)
Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. (2002) (117)
Reinduction chemotherapy in small cell lung cancer. (1987) (115)
TRAIL therapy in non–small cell lung cancer cells: sensitization to death receptor–mediated apoptosis by proteasome inhibitor bortezomib (2007) (114)
Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. (1999) (114)
A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas (2011) (113)
Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. (2001) (111)
Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia (2012) (106)
Kahalalide F Induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling (2005) (102)
Mutations of epigenetic regulatory genes are common in thymic carcinomas (2014) (102)
p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. (1996) (101)
The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map for Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors (2014) (100)
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). (2003) (100)
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. (2012) (100)
Determinants of CPT-11 and SN-38 activities in human lung cancer cells. (1998) (99)
Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. (2010) (99)
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib (2010) (99)
Neuromedin B is present in lung cancer cell lines. (1992) (99)
Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. (2002) (99)
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. (2008) (98)
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. (2014) (98)
Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer (2009) (95)
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30 (2008) (94)
Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. (2001) (92)
Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. (2000) (91)
Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. (2011) (89)
Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. (2004) (89)
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. (1997) (89)
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. (2002) (88)
Multidrug resistance proteins and other drug transport-related resistance to natural product agents. (1995) (88)
Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. (2006) (88)
[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. (2010) (88)
The multilayered postconfluent cell culture as a model for drug screening. (2000) (87)
Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. (1998) (87)
Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. (2003) (87)
P-glycoprotein--a marker of cancer-cell behavior. (1995) (86)
The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. (2003) (86)
Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas (2009) (86)
Src as a potential therapeutic target in non-small-cell lung cancer. (2008) (85)
Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC (2014) (85)
Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States (2015) (85)
EGFR inhibitors: what have we learned from the treatment of lung cancer? (2005) (85)
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). (2008) (85)
Prognostic relevance of P-glycoprotein expression in breast cancer. (1995) (84)
Detection of cytokeratin-19 transcripts by reverse transcriptase-polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients. (1997) (83)
Checklist of Mediterranean Seaweeds. III. Rhodophyceae Rabenh. 1. Ceramiales Oltm. (2001) (82)
The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (81)
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. (2014) (81)
Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines (2000) (81)
Human natural killer T cells acquire a memory-activated phenotype before birth. (2000) (80)
LAMC2 enhances the metastatic potential of lung adenocarcinoma (2015) (79)
A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies (2010) (78)
Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. (2009) (77)
The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients (2007) (76)
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors (2012) (76)
Cancer of the esophagus and gastric cardia: recent advances. (2004) (75)
Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. (2002) (75)
Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib (2011) (75)
Thymoma: update for the new millennium. (2001) (75)
Oncolytic Activity of p53-Expressing Conditionally Replicative Adenovirus AdΔ24-p53 against Human Malignant Glioma (2004) (75)
Morbidity and mortality in the surgery arm of EORTC 08941 trial (2005) (74)
C-MET inhibitors for advanced non-small cell lung cancer (2018) (74)
EGFR and K-ras Mutation Analysis in Non-Small Cell Lung Cancer: Comparison of Paraffin Embedded versus Frozen Specimens (2007) (73)
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. (1996) (73)
A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study (2014) (72)
The IASLC/ITMIG Thymic Malignancies Staging Project: Development of a Stage Classification for Thymic Malignancies (2013) (72)
Expression and localization of inhibitor of apoptosis proteins in normal human tissues. (2006) (72)
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. (2016) (72)
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. (2001) (72)
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). (2008) (72)
How should we analyse FDG PET studies for monitoring tumour response? (2006) (71)
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. (1999) (70)
A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941) (2005) (70)
MicroRNA Expression and Clinical Outcome of Small Cell Lung Cancer (2011) (70)
Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. (2002) (70)
Next generation oncology drug development: opportunities and challenges (2009) (70)
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. (2006) (69)
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis (2015) (69)
EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection (2012) (68)
The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer (2018) (68)
A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). (2013) (68)
The Potential of Antiangiogenic Therapy in Non–Small Cell Lung Cancer (2007) (68)
DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? (1995) (67)
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. (1995) (67)
Tyrosine kinase inhibitors in lung cancer. (2012) (67)
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the N and M Components for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors (2014) (67)
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. (2000) (67)
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib (2010) (66)
Second-line chemotherapy and its evaluation in small cell lung cancer. (1999) (66)
MRP is frequently expressed in human lung‐cancer cell lines, in non‐small‐cell lung cancer and in normal lung (1996) (65)
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. (2005) (65)
Targeting the Epigenome in Lung Cancer: Expanding Approaches to Epigenetic Therapy (2013) (65)
Biology and management of malignant pleural mesothelioma. (2006) (65)
Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. (1995) (64)
Histone deacetylase inhibitors in cancer therapy (2008) (64)
Polarization of Vα24+ Vβ11+ Natural Killer T Cells of Healthy Volunteers and Cancer Patients Using α-Galactosylceramide-loaded and Environmentally Instructed Dendritic Cells (2003) (64)
The Role of Gefitinib in Lung Cancer Treatment (2004) (63)
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. (2013) (63)
Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N 2 Non – Small-Cell Lung Cancer (2007) (62)
Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years. (2012) (62)
MDR1/P-glycoprotein expression in colorectal cancer. (1995) (61)
Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer (2014) (60)
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). (2003) (59)
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. (2004) (59)
CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. (1998) (59)
Treatment of malignant thymoma (2005) (58)
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. (2009) (58)
Role and Relevance of TrkB Mutations and Expression in Non–Small Cell Lung Cancer (2011) (58)
Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). (2015) (58)
Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958). (2003) (58)
Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. (1996) (57)
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone (2009) (57)
A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies (2018) (56)
Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. (2018) (56)
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. (2011) (56)
Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells. (2002) (55)
Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling (2015) (54)
Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. (2014) (54)
Expression and Mutational Status of c-kit in Thymic Epithelial Tumors (2010) (54)
Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment (2019) (54)
Phase II trial of ZD0473 as second-line therapy in mesothelioma. (2002) (54)
Biomarkers in Early-Stage Non–Small-Cell Lung Cancer: Current Concepts and Future Directions (2014) (54)
Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations (2017) (54)
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. (2010) (54)
HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. (2005) (53)
Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. (1992) (53)
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells (2012) (53)
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. (2000) (53)
Clinical resistance to topoisomerase-targeted drugs. (1998) (53)
Insulin‐like growth factor‐1 receptor and phosphorylated AKT‐serine 473 expression in 132 resected thymomas and thymic carcinomas (2010) (53)
Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. (2000) (52)
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol‐3 kinase pathways in non‐small cell lung cancer cells (2006) (52)
Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. (2010) (52)
Combined Pan‐HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study (2016) (51)
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non–small cell lung cancer cell line NCI-H460 (2007) (51)
Homodimerization Antagonizes Nuclear Export of Survivin (2007) (51)
MEK inhibitors under development for treatment of non-small-cell lung cancer (2018) (50)
Caelyx in malignant mesothelioma: a phase II EORTC study. (2000) (50)
Topoisomerase IIα and other drug resistance markers in advanced non-small cell lung cancer (2001) (50)
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. (1997) (50)
A population‐based assessment of mortality and morbidity patterns among patients with thymoma (2011) (50)
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. (2006) (49)
Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy. (2012) (48)
MRP gene overexpression in a human doxorubicin‐resistant SCLC cell line: Alterations in cellular pharmacokinetics and in pattern of cross‐resistance (1995) (48)
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). (2013) (48)
Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2. (2004) (48)
Human natural killer T cells acquire a memory-activated phenotype before birth (2000) (47)
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer (2011) (47)
Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. (1991) (46)
Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation. (2007) (46)
Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. (1998) (46)
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. (1997) (45)
PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). (2010) (45)
Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. (2004) (45)
Multidrug resistance from the clinical point of view. (1991) (45)
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors (2003) (44)
A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors (2007) (44)
Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown (2006) (44)
Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. (2005) (44)
Clinical impact of novel treatment strategies (2002) (44)
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR‐tyrosine kinase inhibitors (2013) (44)
LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers. (2020) (44)
Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. (2010) (44)
Drug Development: Portals of Discovery (2012) (44)
The determination of gemcitabine and 2'-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. (2007) (44)
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients (2008) (43)
An update on European randomized studies in non-small cell lung cancer. (1998) (43)
Dose-Finding Study of the Multitargeted Tyrosine Kinase Inhibitor SU6668 in Patients with Advanced Malignancies (2005) (43)
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. (2019) (43)
Cryptobenthic fishes of the “Ciclopi Islands” marine reserve (central Mediterranean Sea): assemblage composition, structure and relations with habitat features (2004) (43)
Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. (2016) (43)
Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. (1999) (43)
HSP-90 Inhibitor Ganetespib is Synergistic with Doxorubicin in Small Cell Lung Cancer (2013) (43)
Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. (1992) (43)
Angiogenesis inhibitors. Drug selectivity and target specificity. (2007) (42)
The role of new agents in the treatment of non-small cell lung cancer. (2002) (42)
Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. (1994) (41)
A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC). (2006) (41)
Combined Small Cell Carcinoma of the Lung: Is It a Single Entity? (2017) (41)
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer (2007) (41)
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). (2005) (41)
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. (2018) (41)
Reproducibility of the WHO classification of thymomas: practical implications. (2013) (41)
Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. (2017) (41)
Treatment of Advanced Thymoma and Thymic Carcinoma (2008) (41)
A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: Preliminary results of a phase IB study (2005) (41)
Acupuncture treatment for persistent hiccups in patients with cancer. (2010) (41)
Systemic Treatment of Malignant Thymoma: A Decade Experience at a Single Institution (2006) (40)
Novel approaches to the treatment of non-small cell lung cancer. (2002) (40)
Why has active immunotherapy not worked in lung cancer? (2015) (40)
Thymic epithelial tumors: From biology to treatment. (2020) (39)
Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling (2009) (39)
[Breast cancer in the early stage]. (2012) (39)
Oncogenes and antioncogenes in lung tumorigenesis. (1996) (39)
Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). (1994) (38)
Clinical pharmacology of carboplatin administered in combination with paclitaxel. (1997) (38)
Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export. (2005) (38)
Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. (1994) (38)
Effects of α‐galactosylceramide (KRN7000), interleukin‐12 and interleukin‐7 on phenotype and cytokine profile of human Vα24+ Vβ11+ T cells (1999) (37)
Severe acute lung injury induced by gemcitabine. (2000) (37)
Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer. (2021) (37)
A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC. (2004) (37)
TWO SUDDEN DEATHS DURING PROPHYLACTIC ANTIEMETIC TREATMENT WITH HIGH DOSES OF DOMPERIDONE AND METHYLPREDNISOLONE (1984) (37)
Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA (2004) (36)
Automated serum peptide profiling using novel magnetic C18 beads off‐line coupled to MALDI‐TOF‐MS (2007) (36)
A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors. (2010) (36)
Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. (2003) (36)
Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. (1991) (36)
Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry (2011) (36)
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors (2016) (35)
A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial. (1996) (35)
Multimodality treatment of malignant germ cell tumours of the mediastinum. (1991) (35)
Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases (2007) (35)
Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. (2010) (35)
Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors (2013) (34)
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. (2008) (34)
Dacomitinib, a new therapy for the treatment of non-small cell lung cancer (2013) (34)
Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. (2016) (34)
The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. (2009) (34)
Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. (1993) (34)
Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. (1995) (34)
Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL (2004) (33)
Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study. (2016) (33)
Sicilian transitional waters: current status and future development (2010) (33)
The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression (2004) (33)
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. (2010) (33)
Current chemotherapeutic possibilities in pancreaticobiliary cancer. (1999) (33)
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH (2020) (33)
Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. (1992) (33)
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. (2012) (33)
Targeted agents: how to select the winners in preclinical and early clinical studies? (2012) (32)
Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung (2020) (32)
Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer (2014) (32)
Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. (1996) (32)
Small cell lung cancer: a slightly less orphan disease after immunotherapy. (2021) (32)
Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor (2007) (31)
A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer. (2005) (31)
Population pharmacokinetics of the novel anticancer agent KRN7000 (2002) (31)
Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. (2000) (31)
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies (2011) (31)
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. (2004) (31)
EMT is associated with, but does not drive resistance to ALK inhibitors among EML4‐ALK non‐small cell lung cancer (2016) (31)
Inverted urothelial papilloma: a lesion with malignant potential. (1988) (30)
HER2 mutations in non-small-cell lung cancer can be continually targeted. (2012) (30)
Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human Vα24+Vβ11+ T cells in vitro (2000) (30)
Epidermal growth factor receptor (EGFR) gene copy number detection in non‐small‐cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization (2007) (30)
Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma (2006) (30)
Emerging protein kinase inhibitors for non-small cell lung cancer (2013) (29)
Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. (1996) (29)
Chemotherapy for thymic tumors: induction, consolidation, palliation. (2011) (29)
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung (2018) (29)
Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia. (1995) (29)
Downregulation of 18F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non–Small Cell Lung Cancer with the mTOR Inhibitor Everolimus (2009) (29)
Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report (2014) (28)
EGFR inhibitors in lung cancer. (2005) (28)
Small-molecule inhibitors of the human epidermal receptor family (2009) (28)
Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study. (2017) (28)
Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer (2018) (28)
Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death. (2019) (28)
The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. (1999) (28)
Second line chemotherapy in small cell lung cancer (1989) (28)
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. (2010) (27)
A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183 (2007) (27)
Teniposide (VM26): an effective treatment for brain metastases of small cell carcinoma of the lung. (1988) (27)
Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. (2004) (27)
A phase II study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma (2002) (27)
Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors (2012) (27)
Phase I clinical evaluation of AZD2171 in combination with gefitinib, in patients with advanced tumors (2005) (27)
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives (2019) (27)
Comparative proteomics analysis of caspase-9-protein complexes in untreated and cytochrome c/dATP stimulated lysates of NSCLC cells. (2009) (27)
Whole Genome and Transcriptome Sequencing of a B3 Thymoma (2013) (27)
Disorders of serum electrolytes and renal function in patients treated with cis-platinum on an outpatient basis. (1985) (27)
The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors (2020) (26)
Heat Shock Protein 90-Sheltered Overexpression of Insulin-Like Growth Factor 1 Receptor Contributes to Malignancy of Thymic Epithelial Tumors (2011) (26)
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. (2002) (26)
Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11 (2005) (26)
Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. (2012) (26)
Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer (2011) (26)
A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I) (2007) (26)
DURABLE RESPONSE IN PATIENTS WITH THYMIC CARCINOMA TREATED WITH PEMBROLIZUMAB AFTER PROLONGED FOLLOW-UP. (2020) (25)
Treatment of metastatic non-small cell lung cancer. (1996) (25)
Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology? (2005) (25)
Cisplatin-containing chemotherapy in the treatment of invasive thymoma: report of five cases. (1985) (25)
The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells (2007) (25)
Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors. (2017) (25)
The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo (2013) (25)
Capillary Isoelectric-Focusing Immunoassays to Study Dynamic Oncoprotein Phosphorylation and Drug Response to Targeted Therapies in Non–Small Cell Lung Cancer (2013) (25)
Caulerpa taxifolia in the northwest Mediterranean : introduced species or migrant from the Red Sea ? (1995) (25)
A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC) (2008) (24)
Targeting HER1/EGFR in cancer therapy: experience with erlotinib. (2005) (24)
Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy (2004) (24)
Novel approaches in cancer immunotherapy. (2016) (24)
Phase I trial of SU14813 in patients with advanced solid malignancies. (2011) (24)
DNA topoisomerases and topoisomerase inhibitors. (1994) (24)
Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion (2021) (24)
Ongoing and future trials of biologic therapies in lung cancer. (2003) (23)
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity. (2018) (23)
Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials (2005) (23)
DNA topoisomerase II poisons and inhibitors. (1997) (23)
Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). (2003) (23)
Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain (2007) (23)
DNA topoisomerase inhibitors. (1993) (23)
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations (2017) (23)
Pleura mesothelioma: combined modality treatments. (2002) (22)
18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients with Thymic Epithelial Tumors (2013) (22)
Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. (2004) (22)
EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer (2005) (22)
Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity (2006) (22)
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. (2001) (22)
Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. (2009) (22)
Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. (2006) (21)
Targeted Therapy for Advanced Thymic Tumors (2010) (21)
A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). (2014) (21)
Early intervention with epoetin-alfa during platinum-based chemotherapy. (2004) (21)
Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations. (2013) (21)
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an “exceptional responder” lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response (2016) (21)
Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours (2005) (20)
Cisplatin triggers apoptotic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner. (2003) (20)
Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. (1994) (20)
Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients. (2018) (20)
Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients. (1996) (20)
Antiangiogenic therapy in nonsmall cell lung cancer (2008) (20)
Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement. (2012) (20)
Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients. (2000) (20)
A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. (2009) (20)
Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984). (2006) (20)
High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer. (2018) (20)
Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. (2010) (20)
Seagrasses along the Sicilian coasts (2010) (19)
Precision oncology in non-small-cell lung cancer: opportunities and challenges (2018) (19)
Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). (2004) (19)
P-615 Phase II trials of gefitinib (‘Iressa’, ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAl 2) (2003) (19)
Multidrug resistance in breast cancer: mechanisms, strategies. (1995) (19)
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells (2009) (19)
A Placebo‐Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First‐Line Treatment of Patients With Advanced Nonsquamous Non–Small‐Cell Lung Cancer and Systemic Inflammation (2018) (19)
Bepridil in combination with anthracyclines in the attempt to reverse anthracycline-resistance in cancer patients (1991) (18)
New drugs in non-small cell lung cancer. An overview. (1995) (18)
Response to crizotinib in ROS1-rearranged non-small-cell lung cancer. (2012) (18)
Lung Cancer Vaccines (2011) (18)
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule (2005) (18)
A phase II study of pembrolizumab in patients with recurrent thymic carcinoma. (2016) (18)
Effects of tumor necrosis factor, alone or in combination with topoisomerase‐ii‐targeted drugs, on human lung cancer cell lines (1990) (18)
Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group. (1996) (18)
Novel agents in the treatment of lung cancer: conference summary statement. (2004) (18)
Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line. (1992) (18)
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials (2021) (18)
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (2018) (18)
Semiautomated Laser Capture Microdissection of Lung Adenocarcinoma Cytology Samples (2012) (18)
Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975. (2002) (17)
Subcellular localization of CrmA: identification of a novel leucine-rich nuclear export signal conserved in anti-apoptotic serpins. (2003) (17)
Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. (2006) (17)
Pembrolizumab in patients with recurrent thymic carcinoma: Results of a phase II study. (2017) (17)
ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic results (2001) (17)
513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study (2015) (17)
Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy. (2004) (17)
Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. (2016) (17)
Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. (2013) (17)
TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cells (2006) (17)
Identification of new drugs in pretreated patients with small cell lung cancer. (1989) (17)
O-147 Surgery after induction chemotherapy: Morbidity and mortality in the first 100 patients of the surgery arm of EORTC 08941 trial (2003) (16)
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer. (1997) (16)
Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer (2006) (16)
Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC) (2007) (16)
Hepatic Arterial Chemotherapy for Colorectal Cancer Metastatic to the Liver (2000) (16)
Lung cancer. Introduction. (2003) (16)
Gefitinib phase II study in second-line treatment of advanced esophageal cancer. (2004) (16)
Dexrazoxane in anthracycline extravasation. (2000) (16)
Pancreaticobiliary cancer: the future aspects of medical oncology. (1999) (15)
Carboplatin Dosage Formulae Can Generate Inaccurate Predictions of Carboplatin Exposure in Carboplatin/Paclitaxel Combination Regimens (1998) (15)
Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy (2001) (15)
The role of thoracic radiation therapy in small cell carcinoma of the lung: a concensus report (1989) (15)
Effects of suramin on human lung cancer cell lines. (1995) (15)
22LBA Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC) (2009) (15)
The role of talactoferrin alfa in the treatment of non-small cell lung cancer (2010) (15)
Molecular predictors of response to pembrolizumab in thymic carcinoma (2021) (15)
The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors (2004) (15)
Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology. (2006) (15)
Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells (2020) (14)
Assessment of Objective Responses Using Volumetric Evaluation in Advanced Thymic Malignancies and Metastatic Non-small Cell Lung Cancer (2011) (14)
A phase I / II study of sepantronium bromide ( YM 155 , survivin suppressor ) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer (2013) (14)
Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC. (2015) (14)
Inheritance of chemical constituents in algae: Tetraprenyltoluquinols of Cystoseira elegans x C. algeriensis (1988) (14)
FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy. (2005) (14)
Phase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC). (2010) (14)
NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors (2012) (14)
Increased expression of differentiation markers can accompany laminin-induced attachment of small cell lung cancer cells. (1992) (14)
Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group. (1992) (14)
Twenty-five years of treating advanced NSCLC: what have we achieved? (2004) (14)
Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer (1996) (13)
Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients (2000) (13)
1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial (2020) (13)
Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). (2010) (13)
Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling. (2001) (13)
Characterization and Management of Cardiac Involvement of Thymic Epithelial Tumors (2013) (13)
Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer. (2019) (13)
Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib (2008) (13)
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC (2018) (13)
An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): Updated analysis of patients enrolled within 12 weeks of completion of chemotherapy. (2014) (12)
Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. (2013) (12)
Teniposide in the treatment of non-small cell lung carcinoma. (1987) (12)
A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer (2018) (12)
High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb). (2019) (12)
Small cell lung cancer and topoisomerases. (1994) (12)
In-vitro schedule-dependency of eo9 and miltefosine in comparison to standard drugs in colon-cancer cells. (1994) (12)
Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer. (1997) (12)
Cisplatin and Etoposide in Chemotherapy-Refractory Advanced Breast Cancer (1988) (12)
Novel Agents in the Treatment of Lung Cancer (2004) (12)
Natural Killer T cells. (2002) (12)
Gemcitabine and paclitaxel combinations in non-small cell lung cancer. (1998) (12)
Stevens-Johnson Syndrome and Fatal Pulmonary Toxicity to Combination Chemotherapy Containing Bleomycin: A Case Report (1986) (12)
An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice (2018) (12)
Phase II trial of sunitinib in patients with thymic epithelial tumors (TET). (2014) (11)
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy (2009) (11)
Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung (1989) (11)
Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studies (2007) (11)
Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort. (1994) (11)
Acute autoimmune hepatitis, myositis, and myasthenic crisis in a patient with thymoma. (2013) (11)
Next-Generation Sequencing: Targeting Targeted Therapies (2015) (11)
Image microarrays (IMA): Digital pathology's missing tool (2011) (11)
EGFR Mutations in Latinos From the United States and Latin America (2016) (11)
Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor. (2001) (11)
New drugs for the management of lung cancer. (1996) (11)
Phase I Trial of Irreversible Pan-Erbb Inhibitor Dacomitinib (DAC) in Combination with ALK/MET Inhibitor Crizotinib (CRIZ) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (10)
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT) (2018) (10)
CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma (2016) (10)
Erratum to: Alien species along the Italian coasts: an overview (2011) (10)
Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report. (2015) (10)
Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition. (2011) (10)
International thymic malignancy interest group. (2010) (10)
Thymoma-associated paraneoplastic polymyositis. (2010) (10)
A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. (2019) (10)
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. (2017) (9)
SDZ PSC 833 in combination with doxorubicin: a phase I and pharmacologic study in solid tumors (1994) (9)
A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim results. (2006) (9)
Scalp hypothermia in the prevention of doxorubicin-induced hair loss. (1988) (9)
The seaweedGracilaria confervoides, an important object for autecologic and cultivation research in the northern Adriatic Sea (1970) (9)
The IASLC Thymic Tumors Staging Project. The Impact of the 8th Edition of the UICC/AJCC TNM Stage Classification of Thymic Tumors: Results of a Survey. (2019) (9)
Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation (2020) (9)
Autologous tumor cell vaccination with PF-3512676 (CPG 7909) and GM-CSF followed by subcutaneous PF-3512676 and IFN-alpha for patients with metastatic renal cell carcinoma. (2006) (9)
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group. (1996) (9)
Induction chemotherapy (CT) in stage IIIA-N2 non-small cell lung cancer (NSCLC): An analysis of different regimens used in EORTC 08941 (2003) (9)
Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies. (2016) (9)
Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening. (1998) (9)
A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression (2021) (9)
Multiorgan autoimmune manifestations associated with thymoma. (2015) (9)
Gefitinib phase II study in second-line treatment of advanced esophageal cancer (2004) (9)
9158 A phase III study of erlotinib as maintenance therapy in NSCLC to delay progression following first-line chemotherapy (SATURN) (2009) (9)
Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer. (1987) (9)
Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis (2020) (9)
Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors. (2020) (9)
Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer? (1998) (9)
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. (2013) (9)
Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report (2021) (9)
Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. (2006) (9)
Bone marrow evaluation in small cell carcinoma of the lung. (1987) (9)
Treatment of thymoma and thymic carcinoma. (2000) (9)
Antiemetic Activity of Oral Lorazepam in Addition to Methylprednisolone and Metoclopramide in the Prophylactic Treatment of Vomiting Induced by Cisplatin. A Double-Blind, Placebo-Controlled Study with Crossover Design (1993) (8)
Signal transduction modulators for cancer therapy: from promise to practice? (2003) (8)
LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study (2019) (8)
Docetaxel and cisplatin as induction chemotherapy in stage IIIA N2 non-small cell lung cancer (NSCLC): An EORTC phase II trial (08984). (2004) (8)
Medical treatment of non-small-cell lung cancer. (2005) (8)
Does downstaging in patients (pts) with IIIA-N2 non-small cell lung cancer (NSCLC) and a response to induction chemotherapy (ICT) influence outcome with surgery (S) or radiotherapy (RT)? An exploratory analysis of EORTC 08941. (2006) (8)
Teniposide alone and in combination chemotherapy in small cell lung cancer. (1992) (8)
A phase (Ph) I/II study of belinostat (Bel) in combination with cisplatin, doxorubicin, and cyclophosphamide (PAC) in the first-line treatment of advanced or recurrent thymic malignancies. (2012) (8)
Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data. (2006) (8)
PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD‐L1–Selected Chemotherapy‐Naive NSCLC Patients: Topic: Medical Oncology (2016) (8)
EORTC LCCG Phase II study of topotecan in combination with cisplatin as second line chemotherapy of sensitive and refractory small cell lung cancer (SCLC) (2000) (8)
Final results of a double-blind placebo-controlled study of adjuvant marimastat in small cell lung cancer (SCLC) patients responding to standard therapy (2001) (8)
Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design. (2016) (8)
Targeted therapy in non-small cell lung cancer. (2002) (8)
Lung cancer in 2013: Refining standard practice and admitting uncertainty (2014) (8)
The expression of TUCAN, an inhibitor of apoptosis protein, in patients with advanced non-small cell lung cancer treated with chemotherapy. (2006) (7)
Lonidamine versus Polychemotherapy in Advanced Non-Small-Cell Lung Cancer. A Preliminary Analysis (1989) (7)
Gemcitabine and Cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 Non-Small Cell Lung Cancer: A phase II study of the EORTC Lung Cancer Cooperative Group (EORTC 08955) (2000) (7)
DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens. (2011) (7)
An eighteen months survey of the artificial reef of Terrasini N/W Sicily the invertebrates (1985) (7)
Drug Resistance in the Treatment of Cancer (1998) (7)
A phase I trial of the novel oral taxane BMS-275183 in patients with advanced solid tumors. (2004) (7)
DNA topoisomerase inhibitors. (1996) (7)
O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC (2020) (7)
IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC). (2020) (7)
A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients. (2001) (7)
Sex and cancer immunotherapy: Current understanding and challenges. (2022) (7)
Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAb), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein. (2013) (7)
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. (2007) (7)
CYB5A and autophagy-mediated cell death in pancreatic cancer (2014) (7)
A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer (2021) (7)
Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors. (2015) (7)
Newer opportunities in systemic therapy of lung cancer. (2008) (7)
Isolated Central Nervous System Metastasis from Ovarian Carcinoma: A Case Report (1989) (7)
Molecular Pathways of Drug Resistance (2004) (7)
Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial. (2019) (7)
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. (2022) (6)
A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC). (2016) (6)
Genotype analysis of the VNTR polymorphism in the SMYD3 histone methyltransferase gene: Lack of correlation with the level of histone H3 methylation in NSCLC tissues or with the risk of NSCLC (2008) (6)
Phase II study of ACNU as second-line treatment in small-cell lung cancer (1992) (6)
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. (2016) (6)
Phase II study of cixutumumab (IMC-A12) in thymic malignancies. (2012) (6)
In vitro sequence-dependent synergistic effect of suramin and camptothecin. (1994) (6)
Phase II study of imatinib in patients with WHO B3 and C thymomas (2008) (6)
Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer (2019) (6)
Intrapulmonary lymph node retrieval: unclear benefit for aggressive pathologic dissection. (2012) (6)
Samples sizes in oncology trials : a survey (2010) (6)
Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment (2004) (6)
Comparison of Methylprednisolone and Metoclopramide in the Prophylactic Treatment of CIS-Platin-Induced Nausea and Vomiting (1984) (6)
Analysis of Deoxycytidine Accumulation in Gemcitabine Treated Patients (2006) (6)
Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial. (2013) (6)
Gemcitabine plus taxane combinations in non-small cell lung cancer. (1999) (6)
Genomics-based early-phase clinical trials in oncology: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. (2014) (6)
Correspondence re: L. Yang et al., Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res., 63: 831-837, 2003. (2003) (6)
Fortis-M, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Oral Talactoferrin Alfa with Best Supportive Care in Patients with Advanced Non-Small Cell Lung Cancer Following Two or More Prior Regimens- by the Fortis-M Study Group (2012) (6)
18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer. (2007) (6)
Challenges in Cancer Molecular Targets and Therapeutics (2011) (6)
Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human V alpha 24+V beta 11+ T cells in vitro. (2000) (6)
Ganetespib for small cell lung cancer (2017) (6)
Chemotherapy for non-small-cell lung cancer (2001) (6)
FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC (2021) (6)
Clinical Practice Guideline Update on Chemotherapy for Stage IV Non – Small-Cell Lung Cancer (2009) (5)
Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer (2018) (5)
The Prognostic Value of Non-Predominant Micropapillary Pattern in a Large Cohort of Resected Invasive Lung Adenocarcinoma Measuring ≤3 cm (2021) (5)
Exercise-induced spontaneous hemothorax insinuates trauma; yet unmasks a lament disorder. (2001) (5)
Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. (2018) (5)
An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC). (2005) (5)
Father-Son Testicular Cancer, Case Report (1983) (5)
Complete remission of metastatic colorectal cancer: a pitfall in a multidrug resistance reversal trial (1994) (5)
Update on Cancer Therapeutics (2006) (5)
Carboplatin (JM 8), Adriamycin and Cyclophosphamide (JAC) in Advanced Ovarian Carcinoma: A Pilot Study (1988) (5)
Phase II study of esorubicin in the treatment of patients with advanced sarcoma. (1989) (5)
C1-04: A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I) (2007) (5)
Feasibility Study of Erlotinib (tarcevaR) Plus Radiotherapy in Patients with Locally Advanced or Recurrent Rectal Carcinoma (2008) (5)
DNA topoisomerase II poisons and inhibitors. (1999) (5)
A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy (2007) (5)
A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC. (2010) (5)
The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. (2013) (5)
In vitro chemosensitivity testing of multilayered microcultures. (1992) (5)
Lung cancer: First-line immunotherapy in lung cancer — taking the first step (2016) (5)
The differential diagnosis of primary lung cancer: inter-observer agreement and contribution of specific diagnostic procedures. (1992) (5)
Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology (2021) (5)
TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells (2019) (5)
Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials (2022) (5)
P2.12-03 Phase I/II Trial Of 177Lu-DOTA0-Tyr3-Octreotate (Lutathera) And Nivolumab for Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (2018) (5)
Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer (2010) (5)
A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133) (2016) (5)
Comprar Drug Resistance in the Treatment of Cancer | Herbert M. Pinedo | 9780521030748 | Cambridge University Press (2007) (5)
Syntaxonomic relationships of the mediterranean phytobenthos assemblages: paleoclimatic bases and evolutive tendencies (1997) (4)
Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature. (2020) (4)
Pharmacodynamics of RAD001 measured by early FDG PET in patients with recurrent NSCLC (2008) (4)
355TiPPhase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC (2015) (4)
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers. (2021) (4)
Safety and activity of Combined AVElumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study. (2020) (4)
Validations and descriptions of European syntaxa of vegetation dominated by lichens, bryophytes and algae (2015) (4)
DNA topoisomerase inhibitors. (1994) (4)
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine (2021) (4)
4'-Deoxydoxorubicin, an inactive drug in small cell lung cancer. (1987) (4)
A single arm, open-label, phase II study to assess the efficacy of lucitanib in patients with FGFR1-amplified squamous NSCLC (sqNSCLC). (2014) (4)
A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former smokers (C/FS) (2008) (4)
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. (2016) (4)
Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors? (2020) (4)
Targeted Therapies in Lung Cancer(招請講演4) (2002) (4)
Pr5 A randomized trial of radical surgery (S) versus thoracicradiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941) (2005) (4)
The European Organization for Research and Treatment of Cancer experience with teniposide: preliminary results of a randomized study in non-small cell lung cancer. (1992) (4)
High doses of methylprednisolone with or without alizapride in the prevention of cisplatin-induced emesis. A randomized, double-blind, crossover study. (1988) (4)
Chest irradiation as an attempt to improve the response after induction chemotherapy in small cell lung carcinoma. (1985) (4)
Immunohistochemical detection of nuclear survivin in NSCLC: a comparison of commercial antibodies (2007) (4)
Combination Chemotherapy for Metastatic Brain Tumors (1981) (4)
Targeted Therapies in Oncology (2007) (4)
A bone biopsy is mandatory in the optimal management of bone lesions in patients with a long-term history of malignancy of the breast. (2000) (4)
57 Gemcitabine (G) in malignant pleural mesothelioma (MPM): A phase II study (1997) (4)
Current phase II data for ZD0473 in patients with mesothelioma who had relapsed following one prior chemotherapy regimen (2001) (4)
Effect of Food on the Pharmacokinetic Behavior of the Potent Oral Taxane BMS-275183 (2008) (4)
Current Controversies in Cancer Are Platinum Compounds Mandatory in the Treatment of Metastatic Non-Small Cell Lung Cancer? (1999) (4)
Epithelial tumors of the thymic gland are rare malignancies. Foreword. (2010) (3)
Publication Rate and Characteristics of Lung Cancer Clinical Trials (2019) (3)
A PCR-aided transcript titration assay (PATTY) to measure topoisomerase I gene expression in human tumor specimens. (1999) (3)
First line tailored chemotherapy in advanced colorectal cancer (ACRC) with 5-fluouracil/leucovorin (5FU/LV) or oxaliplatin/irinotecan chosen by the expression of thymidylate synthase (TS) and dihydropyrimidine (DPD) (2004) (3)
The regulation of CD73 in non-small cell lung cancer. (2022) (3)
Phase I trial of SU014813 in patients (pts) with advanced solid malignancies (2007) (3)
TUCAN / CARDINAL / CARD 8 and apoptosis resistance in non-small cell lung cancer cells (2007) (3)
4′ -epi-doxorubicin in advanced lung cancer (1990) (3)
A phase I study of paclitaxel, carboplatin, and YM155 (survivin suppressor) in subjects with solid tumors. (2011) (3)
Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs) (2016) (3)
Cisplatin and etoposide for locally advanced or metastatic thymoma. A phase II study of the EORTC lung cancer cooperative group (1991) (3)
Phase II study of alpha-interferon plus bleomycin in advanced non-small cell lung cancer. (1989) (3)
Molecular Cancer Therapeutics Association of Polymorphisms in AKT 1 and EGFR with Clinical Outcome and Toxicity in Non – Small Cell Lung Cancer Patients Treated with Gefitinib (2010) (3)
The European Organization for Research and Treatment of Cancer (EORTC) trials of new agents for advanced non-small cell lung cancer. (1988) (3)
A review of Mediterranean macrophytobenthos collections present in Italy: a contribution to the Mediterranean Initiative on Taxonomy (2008) (3)
First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma. (2021) (3)
Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC. (2020) (3)
Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. (2017) (3)
The EGF(R) and VEGF(R) Pathways as Combined Targets for Anti-Angiogenesis Trials in Cancer Therapy (2008) (3)
Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer. (2020) (3)
ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients. (2019) (3)
Met amplification and HSP90 inhibitors (2009) (3)
480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts) (2016) (3)
State of the art in systemic treatment of lung cancer. (2001) (3)
P-485 EGFR mutations do not accurately predict response to erlotinib in first-line monotherapy treatment of advanced non-small-cell lung cancer (2005) (3)
Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872 (1991) (3)
Iron Absorption During Epoetin Alfa Therapy for Chemotherapy-Associated Anaemia (2006) (3)
P1-084: Mammalian target of rapamycin (mTOR) inhibition by RAD001 in patients (pts) with reccurent non-small cell lung cancer (NSCLC): Use of 18F fluorodeoxyglucose positron-emission tomography (FDG-PET) in evaluation of the pharmacodynamic effect (2007) (3)
COMPLETE GENOME SEQUENCING OF A HUMAN B3 THYMOMA (2011) (3)
Macrophytobenthos and the ecological status of coastal waters around Sicily (2010) (3)
Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for patients with extensive-stage small cell lung cancer. (2018) (3)
[Decline in the need for blood transfusions in cancer patients due to the use of epoietin alfa during cisplatin based chemotherapy]. (2001) (3)
Keynote comment: are large-scale cancer-genomics projects ready to use? (2006) (2)
Phase I trial of belinostat in combination with cisplatin (Cis) and etoposide (Etop). (2013) (2)
ResearchHypertension and hand-foot skin reactions related to VEGFR 2 genotype and improved clinical outcome following bevacizumab and sorafenib (2015) (2)
Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non–small cell lung cancer (NSCLC): KEYNOTE-867. (2022) (2)
Dose-Finding Study of theMultitargeted Tyrosine Kinase Inhibitor SU 6668 in Patients with AdvancedMalignancies (2005) (2)
120 Expression of lung resistance-related protein (LRP) in lung cancer (1995) (2)
Abstract P6-18-11: Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+ breast cancer patients with prior anti-HER2 therapy (2019) (2)
Cisplatin and teniposide chemotherapy for advanced non-small cell lung cancer. (1991) (2)
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials (2022) (2)
Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death (2019) (2)
Phase II Study of Divided-Dose Vinblastine in Advanced Cancer Patients (1989) (2)
Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy. (2022) (2)
Multidisciplinary Team Management of Lung Cancer (2007) (2)
MA09.01 A Phase I/II Trial of Dasatinib and Osimertinib in TKI Naïve Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) (2019) (2)
ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients (2019) (2)
The clinical significance of drug resistance in lung cancer (1997) (2)
Understanding molecular diagnostic technology in oncology through the lens of lung cancer. (2018) (2)
Phase I study of vandetanib (V) and bevacizumab (B) combination therapy evaluating the VEGF and EGF signal transduction pathways in adults with solid tumors and NHL. (2016) (2)
P-410 Prognostic factor analysis of EORTC 08983: A randomized phaseIII study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM) (2005) (2)
Overview of past, present and future of the EORTC Lung Cancer Group. European Organisation for Research and Treatment of Cancer. (2002) (2)
Complete remission of colorectal cancer: a pitfall in a multidrug resistance reversal trial (1994) (2)
MA 02.02 Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC (2017) (2)
A nanofluidic immunoassay system to develop proteomic responsive biomarkers in non-small cell lung cancer. (2012) (2)
Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience (2021) (2)
Time-course MALDI-TOF-MS serum peptide profiling of non-small cell lung cancer patients treated with bortezomib, cisplatin and gemcitabine (2008) (2)
P2.07-050 Impact of Steroid Use for Immune Related Adverse Events on Outcomes in Non-Small Cell Lung Cancer (NSCLC) Treated with Checkpoint Inhibitors (2017) (2)
A genomic analysis of large cell neuroendocrine carcinoma versus small cell lung cancer: which is which? (2016) (2)
Novel Treatments for Thymoma and Thymic Carcinoma (2015) (2)
Cardiomyocyte-specific circulating cell-free methylated DNA in esophageal cancer patients treated with chemoradiation (2021) (2)
CA1: PROSPECTIVE ECONOMIC EVALUATION OF ANTIBIOTIC PROPHYLAXIS IN SMALL CELL LUNG CANCER (SCLC) PATIENTS RECEIVING CHEMO THERAPY (1999) (2)
Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies (2012) (2)
Advances in the Management of Lung Cancer (2000) (2)
143TiPIMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC (2017) (2)
Comprar Targeted Therapies in Oncology | Jean-Charles Soria | 9780849393716 | Informa Healthcare (2007) (2)
Topoisomerase I Inhibitors: Current Use and Prospects (2012) (2)
A phase 1 B, open-label, dose-escalation study of bortezomib (Btz) in combination with gemcitabine (G) and cisplatin (C) in the first-line treatment of patients with advanced solid tumors: preliminary results (2005) (2)
P1.01-47 Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) (2018) (2)
FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer. (2004) (2)
Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group. (1992) (2)
Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer. (2018) (2)
The IASLC Thymic Epithelial Tumors Staging Project: unresolved issues to be addressed for the next 9th edition of the TNM classification of malignant tumors. (2022) (2)
Drug Resistance In The Treatment of Cancer: Contents (1998) (2)
176 POSTER Outcome of three Phase I trials of the marine compound ES-285 (3 hour infusion) in patients with refractory solid tumors (2008) (2)
Cisplatin and carboplatin in combination chemotherapy for advanced ovary cancer. (1989) (2)
MA20.05 Follow-Up Update of 2 Phase II Studies of Pembrolizumab in Thymic Carcinoma (2019) (2)
Loss of 18 q 22 . 3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer (2012) (2)
A phase II, monotherapy study of YM155, a novel survivin suppressant, in previously treated advanced stage non-small cell lung cancer (NSCLC) (2007) (2)
The Role of EGFR-TK Inhibition in Non-Small Cell Lung Cancer (2005) (1)
Views and news from Melbourne, the Sixth World Conference on Lung Cancer. The EORTC Lung Cancer Co-operative Group. (1992) (1)
"Pseudocavitation" in thymic carcinoma during treatment with sunitinib. (2013) (1)
Publication rate of registered clinical trials in lung cancer. (2019) (1)
[Chemotherapy of a second instance of carcinoma of the ovary]. (1984) (1)
Contribution of metalloproteinase-dependent and urokinase-dependent proteolytic pathways in lung cancer-mediated dissolution of extracellular matrix (ECM). (2000) (1)
Abstract 1143: Unraveling the role of CYB5A in pancreatic ductal adenocarcinoma (PDAC): correlation with clinical outcome and functional characterization in the modulation of autophagy and oncogenic phenotypes. (2013) (1)
[Role of chemotherapy in non-small cell lung carcinoma]. (1996) (1)
EGFR mutations in Latinos from the United States and Latin America. (2015) (1)
64 POSTER Phase I study of pemetrexed followed by daily enzastaurin in patients with advanced or metastatic cancer (2006) (1)
P2.06-024 Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1: Topic: Phase III (2017) (1)
Pilot study of teniposide in combination chemotherapy for small cell lung cancer. (1991) (1)
Antiangiogenesis induced tumor cavitation in lung cancer. (2009) (1)
L09.03THE EVALUATION OF SELUMETINIB A MEK-INHIBITOR WITH AND WITHOUT THE ADDITION OF ERLOTINIB IN KRAS MUTATED NON-SMALL CELL LUNG CANCER (2013) (1)
705 POSTER Evaluation of thyroid function in an open-label Phase I study of AZD2171 with gefitinib (2007) (1)
1115 POSTER Epidermal Ggrowth Factor Receptor Inhibitor (EGFRI)-associated rash: a suggested novel management paradigm. A consensus position from the EGFRI Dermatologic Toxicity Forum (2007) (1)
[Novel approaches; improved diagnosis and therapy with DNA microarrays. I. Technology and data analysis]. (2003) (1)
Comparison of enzastaurin pharmacokinetics and safety in the once daily (QD) and twice daily (BID) dose regimens: A phase I study (2007) (1)
Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer. (2021) (1)
Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. (2010) (1)
[Novel approaches; improved diagnostics and therapeutics with DNA microarrays. II. Applications]. (2003) (1)
A phase 1B study of SNX-5422 plus carboplatin (C) and paclitaxel (P) in patients with advanced non-small-cell lung cancer (NSCLC). (2017) (1)
Targeted Therapies in Oncology, Second Edition (2013) (1)
Combination of gemcitabine and cisplatin (GC) chemotherapy for advanced or recurrent nasopharyngeal cancer (NPC): A phase II study. (2004) (1)
Doxorubicin and etoposide in the treatment of advanced measurable breast cancer. (1990) (1)
Pharmacokinetics (PK) and pharmacodynamics (PD) of SDZ PSC 833, a novel multidrug resistance reversing agent, in phase 1 trials with chemotherapeutic agents (1997) (1)
Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report (2009) (1)
DEEP RHODOLITH BEDS IN THE USTICA ISLAND (SICILY, SOUTHERN TYRRHENIAN SEA): A SEDIMENTARY AND PALEOECOLOGICAL APPROACH (2018) (1)
A phase I study of intravenous artesunate (IV AS) in patients with solid tumors. (2015) (1)
Second line chemotherapy in small (1989) (1)
Abstract 2995: MicroRNA expression and outcome of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program (IALT-Bio) (2010) (1)
Clinical Pharmacology of Carboplatin Administered in Alternating Sequence with Paclitaxel in Patients with Non-Small Cell Lung Cancer: A European Cancer Centre (ECC) Study (1996) (1)
Human dosimetry and tumor kinetics of 111In CHX-A" DTPA trastuzumab in solid tumors using gamma-camera imaging (2011) (1)
CUSTOM (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies trial): A radical redesign of clinical trial structure—Use of mass customization and product postponement. (2013) (1)
What Can We Learn From the French Experience in Systemic Treatment of Thymic Epithelial Tumors? (2018) (1)
Abstract 5521: Application of an automated capillary isoelectric-focusing immunoassay to study dynamic oncoprotein phosphorylation in non-small cell lung cancer and for evaluating drug response to targeted therapies. (2013) (1)
Clinical potential of proteasome inhibition in solid tumours (2004) (1)
Platinum Compounds in Lung Cancer: Current Status (2009) (1)
Expression of multidrug resistance (MDR) genes in normal breast tissue, primary and advanced breast cancer and treatment outcome: 129 (1994) (1)
10th Conference on DNA Topoisomerases in therapy. (1999) (1)
Molecular mechanisms underlying the synergistic interaction of erlotinib , an epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor , with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells (2008) (1)
Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S). (2010) (1)
Abstract 5480: Effects of UGT1A1 genotype on pharmacokinetics and toxicities of belinostat administered by continuous infusion in two clinical trials (2015) (1)
Best practices and guidelines for the management of thymic epithelial tumors (2019) (1)
Long-Term Survival and Complete Response to Adriamycin and Etoposide in a Case of Hepatocellular Carcinoma (1986) (1)
344 EGFR inhibitors in the treatment of lung cancer (2003) (1)
AParallel Dose-Escalation Study ofWeekly andTwice-Weekly Bortezomib in Combinationwith Gemcitabine and Cisplatin in the First-LineTreatment of Patients with Advanced SolidTumors (2007) (1)
Thymomas: the need for prospective studies. (2013) (1)
Radiotherapy with/without cisplatin following chemotherapy in limited small-cell lung cancer. (1998) (1)
Prognostic factors and combined histologies in 205 resected small cell lung cancer (SCLC) patients. (2017) (1)
Clinical trials report on ongoing trials in lung cancer. (1997) (1)
Therapeutic Effects of XPO 1 Inhibition in Thymic Epithelial Tumors (2017) (1)
Combination of gemcitabine and cisplatin (GC) chemotherapy for advanced or recurrent nasopharyngeal cancer (NPC): A phase II study (2004) (1)
Drug Resistance In The Treatment of Cancer: Topoisomerase genes and resistance to topoisomerase inhibitors (1998) (1)
Comprar Principles of Molecular Oncology | Bronchud, Miguel H. | 9781934115251 | Springer (2008) (1)
Eighth conference on DNA topoisomerases and therapy Amsterdam, The Netherlands 15–17 October 1997 (1998) (0)
Grand Challenges in Oncology (2011) (0)
AB007. OS02.01. The integrated genomic landscape of thymic epithelial tumors: a report by the TCGA research network (2017) (0)
Apoptosis Pathways and New Anticancer Agents (2008) (0)
Abstract LB-314: Array comparative genomic hybridization of thymic epithelial tumors identifies loss of CDKN2A as a prognostic factor and BCL2 family members as targets for therapy (2011) (0)
Author's Reply. (2019) (0)
Review of taxonomy situation of marine vegetables in Mediterranean Countries within the Mediterranean Initiative on Taxonomy (MIT) (2008) (0)
Schedule-dependent bortezomib modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells (2008) (0)
Effect of treatment on the regression and growth rates of thymic epithelial tumors (TETs). (2015) (0)
P2.01-041 Integrated Proteo-Genomics Analyses Reveal Extensive Tumor Heterogeneity and Novel Somatic Variants in Lung Adenocarcinoma: Topic: Proteins in Lung Cancer and Proteomics (2017) (0)
33 P - A model to assess cost-effectiveness of prophylaxis of febrile neutropenia (1996) (0)
Commentary (Giaccone/Barlesi): Perspectives on Salvage Therapy for Non–Small-Cell Lung Cancer (2005) (0)
teniposide , and eisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung (0)
Abstract 4191: Thymidylate synthase accelerates development of pituitary tumors in Men1 knockout mice (2010) (0)
Paclitaxel triggers apoptosis through mitochondria-dependent and independent pathways in non-small-cell lung cancer (NSCLC) cells (2000) (0)
Effects of Suramin on Human Lines Lung Cancer Cell (1995) (0)
211 Expression of topoisomerase IIalpha; (TOPIIα), lung resistance-related protein (LRP) and multidrug resistance-related protein (MRP) in advanced non-small cell lung cancer (NSCLC) in relation to sensitivity to chemotherapy (1997) (0)
MS08.03 Optimal Management of Metastatic Thymic Carcinoma (2019) (0)
Subject Index Vol. 56,2012 (2012) (0)
[Clinical thinking and decision making in practice. A patient with anal cancer and hypercalcemia]. (2000) (0)
Mitomycin C, teniposide, and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung (2004) (0)
High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results. (1985) (0)
EGFR gene copy number detection in non small cell lung cancer: A comparison of chromogenic in situ hybridization (CISH) versus f luorescent in situ hybridization (FISH) (2007) (0)
Suramin Activity in Lung Cancer Cell Lines 245 Table 1 (2003) (0)
BH 3-only protein noxa and activation of caspase-9 in the non-small cell lung cancer cell line NCI-H 460 (2008) (0)
Fully Human IgG 1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies (2010) (0)
KEYNOTE-867: Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab in Patients with Unresected Stage I or II Non–Small-Cell Lung Cancer (NSCLC) (2022) (0)
PL3-04: Advances in molecular targeted therapies (2007) (0)
Targeted Therapies for Non-Small-Cell Lung Cancer (2012) (0)
Abstract 2026: CHK1 inhibition synergizes with cisplatin to promote mitotic cell death via activation of caspase 2 and downregulation of E2F1 in small cell lung cancer (2017) (0)
In vitro evaluation of myelotoxicity induced by antineoplastic drugs. (1986) (0)
Glioblastoma-derived factors induce STAT3 phosphorylation and hamper human dendritic cell and Langerhans cell differentiation (2008) (0)
The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer (2018) (0)
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2022) (0)
Phase I clinical and pharmacokinetic (PK) study of gemcitabine (GEM) given by hepatic arterial infusion (HAI) (2005) (0)
77 Randomised comparison of alternating or sequential schedules of chemoradiotherapy in limited small cell lung cancer (SCLC) trial of the EORTC LCCG (08877) (1995) (0)
Marine habitats: vegetation (2009) (0)
Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells (2020) (0)
Abstract 1776: Exploring anetumab ravtansine in a preclinical model of thymic carcinoma (2020) (0)
Biological Properties Distinguishing SCLC From NSCLC Cell Lines (2007) (0)
Commentary (2005) (0)
Clinical trials with angiogenesis inhibitors (2009) (0)
ANTIFRICTION BEARINGS FOR HIGH-SPEED MEANS OF TRACTION (1973) (0)
Cancer Therapy : Preclinical The Janus Kinases Inhibitor AZD 1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo (2013) (0)
Systemic Treatment of Non-Small Cell Lung Cancer (2012) (0)
PD-037 Early and late toxicity of a phase III study randomizingnon-small cell lung cancer (NSCLC) patients to sequential (S) or concurrent (C) chemoradiotherapy (CRT) EORTC 08972-22973 (2005) (0)
Le fanerogame marine in Sicilia (2008) (0)
Abstract B96: Gene-expression profiling of human metastatic non-small cell lung cancer cells enriched by repeated intracardiac injection in mice (2013) (0)
Recurrence of epigenetic gene mutations in thymic epithelial carcinomas revealed by targeted exome sequencing of cancer-associated genes. (2014) (0)
Gemcitabine induced cell cycle disturbances and apoptosis in lung cancer cell lines; Basis for combination therapy with topotecan and taxol (1999) (0)
Management of thymic epithelial tumors (TETs) at the National Cancer Institute (NCI). (2011) (0)
Human Cancer Biology Role and Relevance of TrkB Mutations and Expression in Non – Small Cell Lung Cancer (2011) (0)
Abstract 2146: DNA copy number profiles associated with clinical outcome in advanced colorectal cancer patients treated with folfiri and aliri regimens (2010) (0)
Shuttling of inhibitor of apoptosis proteins (IAP) as a regulatory mechanism for tumor progression (2006) (0)
Sunitinib effective for rare thymus cancer. (2015) (0)
Abstract 4893: AKT1 signaling negatively regulates invasion and metastasis of non-small cell lung cancer cells carrying mutations in KRAS or EGFR (2017) (0)
Abstract 1999: A targeted exome sequencing platform for routine clinical molecular profiling of advanced thoracic malignancies relevant to targeted therapy. (2013) (0)
Eradicating lung cancer cells with an adenoviral vector expressing TRAIL (2003) (0)
Reply to A. Stenzinger et al. (2015) (0)
Abstract 2724: Collaborative regulation of cell cycle progression by Chk1 and E2F1 in small cell lung cancer cells (2016) (0)
University of Groningen Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11 Oosterhoff, (2005) (0)
NKT Cells During HIV Type 1 Infection + 11 b V+ 24 a Selective Decrease in Circulating V (2002) (0)
[Neurological sequelae in outpatient neonates admitted to an intensive care unit in the first year of its activity. Control up to 2 years of age]. (1984) (0)
[Clinical experience with the use of dopamine in pre-term neonates with the respiratory syndrome]. (1983) (0)
Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. EORTC Lung Cancer Cooperative Group. (1989) (0)
[Spontaneous chylothorax in intensive therapy of a very low-weight newborn infant with septicemia caused by Enterobacter cloacae]. (1983) (0)
Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer (2014) (0)
Chapter 3. Bevacizumab (Avastin) (2008) (0)
FOLFOX 3 in heavily pretreated patients with metastatic colorectal cancer (0)
Suggestions for teaching (2008) (0)
First line tailored chemotherapy in advanced colorectal cancer (ACRC) with 5-fluouracil/leucovorin (5FU/LV) or oxaliplatin/irinotecan chosen by the expression of thymidylate synthase (TS) and dihydropyrimidine (DPD). (2004) (0)
A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers. (2015) (0)
CYB5A in pancreatic ductal adenocarcinoma (PDAC): Correlation with outcome and functional characterization in the modulation of autophagy and oncogenic phenotypes (2014) (0)
Signal Transduction Inhibitors of the HER Family (2013) (0)
Functional consequences of nuclear-cytoplasmic localization and transport of apoptosis inhibitors Survivin and CrmA (2007) (0)
In Memory of Professor John Gordon McVie: Bringing People Together 13 January 1945 – 20 January 2021 (2021) (0)
P-434 Diagnostic Pathology Review of EORTC 08983: A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM) (2005) (0)
[The partial parenteral nutrition of preterm infants with a body weight < 1000 g: the effects of an infusion of human albumin on plasma amino acid concentration]. (1993) (0)
High-Risk Non-Small Cell Lung Cancer Treated With Active Scanning Proton Beam Radiation Therapy and Immunotherapy (2022) (0)
Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations (2017) (0)
Imaging , Diagnosis , Prognosis Loss of 18 q 22 . 3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer (2012) (0)
Gefitinib: A Viewpoint by Giuseppe Giaccone (2002) (0)
Next generation sequencing of thymomas and thymic carcinomas (2015) (0)
Cancer Therapy : Clinical Phase II Study of Single-Agent Navitoclax ( ABT-263 ) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer (2012) (0)
Response to: intrapulmonary lymph node retrieval. (2013) (0)
Contents Vol. 56,2012 (2012) (0)
Molecular mechanisms underlying cell death induced by the microtubule interacting agents paclitaxel, discodermolide and epothilone B in non-small cell lung carcinoma (NSCLC) cell lines (2005) (0)
Abstract 5372: Mechanisms of synergy of histone deacetylase inhibitors, belinostat and depsipeptide, with DNA damaging agents, etoposide and cisplatin in small cell lung cancer cell lines (2010) (0)
Edited on behalf of the International Foundation pro Herbario Mediterraneo by (1991) (0)
TOPOISOMERASE II AND DRUG SENSITIVITY IN HUMAN LUNG CANCER CELLS MATERIALS AND METHODS Cell Lines and Cytotoxicity Assay (2006) (0)
P1.12-04 A Phase I Study of the 177Lu-DOTA0-Tyr3-Octreotate in Combination with Nivolumab in Patients with Extensive-Stage Small Cell Lung Cancer (2019) (0)
Standard versus alternating non-cross resistant chemotherapy in extensive disease small cell lung cancer: an EORTC study (1996) (0)
48 The role of biomarkers in selecting the right targeted agent to combine with chemotherapy (2009) (0)
[Monitoring of neuron specific enolase (NSE) in patients with a diagnosis of pulmonary microcytoma. Preliminary results]. (1987) (0)
Original Paper Etoposide in Malignant Pleural Mesothelioma: Two Phase II Trials of the EORTC Lung Cancer Cooperative Group (1997) (0)
61P IMpower110: Exploratory analyses of the impact of first-line (1L) atezolizumab on the efficacy of next-line of therapy in PD-L1–selected NSCLC (2021) (0)
D2-06: The impact of EGFR and KRAS genotype in chemotherapy-naive patients with advanced non-small cell lung cancer treated with erlotinib (2007) (0)
172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors (2022) (0)
Drug Resistance In The Treatment of Cancer: Enhancing drug effectiveness by gene transfer (1998) (0)
OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib (2009) (0)
Update on the systemic treatment of lung cancer. (2002) (0)
Array-based comparative genomic hybridization analysis to identify prognostic markers for resected pancreatic cancer. (2011) (0)
The effect of food on the pharmacokinetics of BMS-275183, a novel oral taxane, in patients with advanced solid malignancies (2005) (0)
1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial (2022) (0)
Lung Cancer Cells CellInduced by Microtubule Stabilizing Agents in Non-Small Cathepsin B Mediates Caspase-Independent Cell Death (2004) (0)
Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations (2022) (0)
A Multilayered Postconfluent Tumor Cell Culture System for in vitro Drug Screening (1996) (0)
644 POSTER The novel oral taxane BMS275183 has a favorable activity and toxicity profile in a twice weekly schedule; Preliminary findings from an extended phase I trial (2006) (0)
Lung Cancer Cell Line NCI-H 460 and Mitochondria-controlled Manner in the Non-Small Cell Chemotherapy Triggers Apoptosis in a Caspase-8-dependent Updated (2000) (0)
Lung cancer. (2005) (0)
Bortezomib triggers strong activation of mitochondria-dependent apoptosis in NSCLC cells accompanied by up-regulation of BH3-only protein NoxA and restores effective activation of caspase-9 (2006) (0)
Preventie en therapie van tumoren (2002) (0)
Serial plasma genotyping of patients with EGFR-mutant lung cancer treated with ASP8273 demonstrates acquired resistance mediated by EGFR C797S (2016) (0)
Comparing the results of cost-effectiveness analyses coducted in Germany (D) and the Netherlands (NL) for antibiotica prophylaxis in small cell lung cancer (SCLC) patients (2000) (0)
Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non–small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial. (2022) (0)
Abstract 3355: Comparison of CD133, uPAR, and CXCR4 expression in lung cancer cell lines under normal and spheroid culture conditions (2010) (0)
Poster session 5 : Erb receptors and signalling (2005) (0)
Sdz Psc 833 in combination with doxorubicin (1994) (0)
Multi-Institutio nal R andomized P hase I I T rial o f G efitinib f or Previously T reated P atients W ith A dvanced N on-Small-Cell Lung C ancer (2003) (0)
Perspectives on salvage therapy for non-small-cell lung cancer: Commentary (2005) (0)
560 Kahalalide F (KF) induces apoptosis-independent cell death that involves ErbB3 downregulation and inhibition of Akt signalling (2004) (0)
312 The prognostic role of mesothelin expression and its association with KRAS mutation in advanced lung adenocarcinoma (2014) (0)
[Effect of petrochemical pollutants on the aquatic plants of Porto Torres (Sardinia, Italy): methodologies of data analysis and interpretation]. [French] (1981) (0)
Reply to Dr. Goto's Letter: "A Thymoma Mouse Model Harboring a Gtf2i L424H Mutation". (2022) (0)
Early non small cell lung cancer: the need for combined treatments (1999) (0)
Phase II study of divided-dose vinblastine in advanced breast cancer patients (2004) (0)
Dramatic Response to Sequential BRAF Inhibition in BRAF V600E-Mutant Metastatic Lung Adenocarcinoma. (2018) (0)
Atezolizumab in lung cancer—appreciating the differences (2016) (0)
Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities (2022) (0)
Abstract 2787: Modulation of autophagy and oncogenic phenotypes through CYB5A-TRAF6 signaling influence prognosis of resected and metastatic pancreatic cancer (2014) (0)
Reply to M.C. Garassino et al (2011) (0)
Lung cancer. (2001) (0)
Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer (AEGC). (2016) (0)
P2.04-019 A Peripheral Immune Signature Associated with Clinical Activity of Sunitinib in Thymic Carcinoma: Topic: Thymic Malignancies Clinical and Translational (2017) (0)
48 Phase II trials of etoposide in malignant pleural mesothelioma (1997) (0)
P-393 Treatment related quality of life findings in patients withmalignant pleural mesothelioma: An international randomized Phase III study of cisplatin with or without raltitrexed (2005) (0)
[Piperacillin and amikacin in the treatment of infections in neoplasm patients with granulocytopenia]. (1989) (0)
P2.03a-014 A Dose-Finding and Phase 2 Study of Ruxolitinib plus Pemetrexed/Cisplatin for Nonsquamous Non–Small Cell Lung Cancer (NSCLC) (2017) (0)
74 INVITED How to exploit the apoptic machinery (2007) (0)
Targeting ErbB receptors as anticancer therapy: factors of sensitivity and resistance (2005) (0)
Clinical relevance of drug resistance: Where do we stand now and where are we going to ? (1994) (0)
Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment. (2004) (0)
A phase I study of IMC-11F8, a recombinant human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors (2007) (0)
Ongoing clinical trials in lung cancer. (1996) (0)
Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or Without Pembrolizumab in Patients with Inoperable Stage I/IIA Non–Small-Cell Lung Cancer (NSCLC): KEYNOTE-867 (2020) (0)
Abstract A110: A phase 1 study of PF‐04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor administered twice weekly in patients with refractory solid tumor malignancies and lymphoma (2009) (0)
16 – Humoral and Cellular Immune Dysregulation and Lung Cancer (2018) (0)
The Potential of AntiangiogenicTherapy in Non^Small Cell Lung Cancer (2007) (0)
Therapeutic Options in Locally Advanced Thymoma (1997) (0)
Abstract 5466: The role of fibroblast growth factor receptor 1 (FGFR1) in small cell lung cancer (SCLC). (2013) (0)
MicroRNA Expression and Outcome in Resected NSCLC—Response (2011) (0)
Lymph node (LN) status is a highly significant component of staging non-small cell lung cancer (NSCLC). Staging of NSCLC provides prognostic data related to risk of recurrence as well as overall survival (1). Lymph node (2012) (0)
Antigen-Presenting Signaling Events in the Tumor Ecology Associate with Response to Anti-PD-1 Treatment in Lung Cancer (2019) (0)
Drug Resistance In The Treatment of Cancer: Series Editor's Preface (1998) (0)
366 Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial (2021) (0)
Gemcitabine a nd P aclitaxel: P harmacokinetic and P harmacodynamic I nteractions i n P atients With N on-Small-Cell L ung C ancer (1999) (0)
Diagnose van tumoren (2002) (0)
521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC) (2016) (0)
Lung cancer. (2003) (0)
Volumetric analysis of advanced thymic malignancies. (2010) (0)
MDICT Task Force: Methodology for the Development of Innovative Cancer Therapies (2007) (0)
Induction of apoptosis in MMTV/PyMT mammary gland tumors with oral zebularine (2008) (0)
Mutational and functional analysis of the EGFR pathway in NSCLC patients: correlation with prognosis and response to small-molecule EGFR inhibitors (2005) (0)
Abstract 4759: Whole genome sequencing of sequentially acquired lung and lymph node metastatic sites from a never smoker lung adenocarcinoma patient revealed extensive genomic heterogeneity (2015) (0)
MDICT consensus report: Recommendations regarding response criteria, endpoints and study designs for the development of immunotherapy combinations (2018) (0)
[Staging of malignant tumors of the ovary. Observations on the lack of diagnostic procedures. review of 141 cases]. (1984) (0)
UGT1A1 genotype effects on PK, PD and toxicities of belinostat administered by 48 h continuous infusion. (2015) (0)
VEGFR Tyrosine Kinase Inhibition: effects on DC differentiation (2006) (0)
Activated c-Met[pY1003]: A potential marker of intrinsic resistance and therapy target to restore sensitivity to gefitinib (2007) (0)
Clinical Trials Report Oncologic, Endocrine & Metabolic Clinical trials in lung cancer (1997) (0)
CN2 ECONOMIC EVALUATION OF NEW POLY-CHEMOTHERAPY REGIMENS AS ALTERNATIVES TO CISPLATIN PLUS PACLITAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER (2002) (0)
Retraction: A novel tumor suppressor gene, ZFN24, inhibits the development of NSCLC by inhibiting the Wnt signaling pathway to induce cell senescence (2022) (0)
61 Concurrent targeted and chemotherapy treatments is the best way to go. CONTRA (2003) (0)
ctDNA detection of EGFR mutations in NSCLC patients using TargetSelector. (2017) (0)
Cell-free circulating tumor DNA (cfDNA) analysis of advanced thymic epithelial tumors (TETs). (2021) (0)
Array Comparative Genomic Hybridization analysis of resected thymomas on paraffin embedded material (2009) (0)
Validation of a polymerase chain reaction aided transcript titration assay (PATTY) for topoisomerase II in lung cancer samples. (2000) (0)
258 Biology and treatment of thymoma (2010) (0)
542 Abnormalities of FHIT and the FRA3B fragile site at 3p14.2 in lung cancer and associated preneoplastic lesions (1997) (0)
1557PDGTF2I MUTATIONS ARE FREQUENT IN THYMIC EPITHELIAL TUMORS. (2014) (0)
The role of immune checkpoint blockade for treatment of thymic epithelial tumors—a delicate balance between efficacy and side effects (2018) (0)
Prevention and therapy of tumors (2002) (0)
A randomized trial of cisplatin plus paclitaxel versus cisplatin plus teniposide in advanced non-small cell lung cancer (1997) (0)
Sample size in randomized clinical trials in oncology: usefull basic statistical knowledge for the clinician (2009) (0)
1024P Net treatment benefit of OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial (2022) (0)
Chapter 12 CYB 5 A role in pancreatic cancer prognosis and autophagy modulation (2013) (0)
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH (2020) (0)
Abstract 372: Association between pre-treatment biomarkers and survival in metastatic non-small cell lung cancer patients treated with first-line pembrolizumab (2021) (0)
Advances at the Center for Cancer Research at the National Cancer Institute's Medical Oncology Branch. (2007) (0)
Abstract CT288: Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with inoperable stage I/IIA non-small-cell lung cancer (NSCLC): KEYNOTE-867 (2020) (0)
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma ( EORTC trial 08956 ) 1 (2009) (0)
A Knock-in Mouse Model of Thymoma with the GTF2I L424H Mutation. (2022) (0)
New Chemotherapeutic Agents: A Selection of Some of the Most Promising New Drugs (1993) (0)
Overview of pathophysiology and drug targets for non-small-cell lung cancer (2012) (0)
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells Fast (2008) (0)
[Chemotherapy in advanced forms of carcinoma of the ovary]. (1984) (0)
492TiP A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion (2022) (0)
Abstract 1120: Role and relevance of TrkB mutations and expression in non-small cell lung cancer (2011) (0)
LAMC2 as a prognostic marker that promotes metastasis of lung adenocarcinoma through epithelial-mensenchymal transition (EMT). (2013) (0)
Chapter 8 Development of new therapeutic agents for treatment of NSCLC (2011) (0)
D6-07: A seventy two gene signature and survival in completely-resected non-small-cell lung cancer (NSCLC) (2007) (0)
Comprar Systemic Treatment of Non-Small Cell Lung Cancer | Giuseppe Giaccone | 9780199580484 | Oxford University Press (2011) (0)
P-501 Activity of tomudex in malignant mesothelioma (2003) (0)
Chapter 5 Homodimerization Antagonizes Nuclear Export of Survivin (2008) (0)
Abstract 3000: MicroRNA-21 as a biomarker for benefit from adjuvant therapy in resectable pancreatic adenocarcinoma (2010) (0)
Characterization of neurotoxicity induced by anticancer agents (2006) (0)
Paclitaxelic Review of its Use in Non-Small Cell Lung Cancer (2001) (0)
A phase I trial investigating a twice weekly administration of the oral taxane BMS-275183 in patients with advanced solid tumors (2005) (0)
Abstract LB-229: Novel mitochondrial inhibitors hold promise for the eradication of lung cancer stem cells (2016) (0)
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine (2021) (0)
Topotecan, New Advance in Chemotherapy Results and Perspectives (1999) (0)
Detection of clinically significant mutations in the epidermal growth factor receptor missed by direct sequencing using a highly sensitive DNA endonuclease. (2006) (0)
Reproducibility of the WHO classification for thymomas in relation to prognosis (2009) (0)
Abstract A47: Clinical profile of ASP8273, a mutant-selective EGFR inhibitor, in subjects with EGFR-mutation positive non-small cell lung cancer: interim results from an ongoing, phase 1, open-label, dose-escalation study (2015) (0)
Pilot trial of molecular profiling and targeted therapies in advanced thoracic malignancies: Non-small cell lung cancer, small cell lung cancer and thymic malignancies (CUSTOM). (2012) (0)
C-kit proto-oncogene and stem cell factor in germ cell tumors: Preferential coexpression in seminomas (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Giuseppe Giaccone?

Giuseppe Giaccone is affiliated with the following schools:

Giuseppe Giaccone's Academic­Influence.com Rankings

Giuseppe Giaccone's Degrees

Why Is Giuseppe Giaccone Influential?

Giuseppe Giaccone's Published Works

Published Works

What Schools Are Affiliated With Giuseppe Giaccone?

Giuseppe Giaccone's AcademicInfluence.com Rankings